| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Sensus Healthcare, Inc.$2.71
+0 (+0.04%)
F 17Pipeline Score MedTech · Commercial
Market Cap
52.51 M
EPS
-0.47
P/E Ratio
-
Value Trade
87.82 K
SEC Financials
Q1 2026Dilution Risk
25%Revenue
3.39 M
R&D Expenses
1.59 M
Operating CF
-3.75 M
Total Assets
51.55 M
Total Liabilities
6.00 M
Equity
45.54 M
D/E Ratio
12,345
-12.6 %
Week
-20.65 %
1 Month
-17.36 %
3 Month
-17.78 %
6 Month
-4.2 %
5 Year
-48.05 %
All Time
Cash Data
Cash Position
18.33 M
Monthly Burn
1.25 M
Runway
13.7 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
1.81 K
52 Week Range
2.82 - 5.92
% held by Insiders
17.63 %
% held by Institutions
27.5 %
Enterprise Value
34.59 M
Total Shares
16.46 M
Short %
1.48 %
Float Shares
13.33 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F17
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 15%
Micro Cap (rank 770 of 905)
Percentile RankSensus Healthcare, Inc. has significant pipeline risk (17/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SRTS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
SRTS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SRTS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SRTS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SRTS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
SRTS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SRTSSensus Healthcare Reports First Quarter 2026 Financial Results and Business Highlights
Sensus Healthcare has reported its financial results for the first quarter of 2026, along with key business highlights. The report includes details on revenue and operational performance, although specific figures and insights are not provided in the article. The company continues to focus on its strategic initiatives for growth.
Read more →SRTSSensus Healthcare to Report First Quarter 2026 Financial Results and Hold Business Update Conference Call on May 7, 2026
Sensus Healthcare, Inc. will report its first quarter 2026 financial results on May 7, 2026. The company will hold a conference call at 4:30 PM ET to discuss these results and provide a business update. Participants can pre-register for the call or join via dial-in options.
Read more →SRTSSensus Healthcare Files Lawsuit Against SkinCure Oncology for Breach of Contract
Sensus Healthcare has initiated legal action against SkinCure Oncology for breach of contract. This lawsuit highlights significant disputes between the two companies, which could have financial implications. The ongoing legal battle may also divert attention from Sensus Healthcare's primary operations.
Read more →SRTSSensus Healthcare Introduces Sensus Link, Brings Advanced Operating Capabilities to the SRT-100™ Installed Base
Sensus Healthcare has launched Sensus Link, a cloud-based software solution designed to enhance the operational capabilities of its SRT-100 system. This initiative aims to improve workflow and treatment documentation for users, while also creating a recurring revenue opportunity. The company plans to roll out Sensus Link commercially in 2026, targeting both new and existing customers.
Read more →SRTSSensus Launches Sensus Healthcare Financial Services to Facilitate Customer Acquisition of SRT Technology
Sensus Healthcare has launched a new program, Sensus Healthcare Financial Services, aimed at simplifying the acquisition of its superficial radiotherapy systems for dermatology practices. This initiative offers flexible financing options and is designed to enhance financial visibility and reimbursement certainty. The program is expected to streamline the purchasing process, making it more accessible for healthcare providers.
Read more →SRTSSensus Healthcare to Report Fourth Quarter and Full Year 2025 Financial Results and Hold Business Update Conference Call on February 12, 2026
Sensus Healthcare, Inc. will report its fourth quarter and full year 2025 financial results on February 12, 2026. A conference call will follow at 4:30 p.m. Eastern time, where management will discuss the results and provide a business update. Participants can pre-register for the call or join via dial-in options.
Read more →SRTSPompano Veterinary Oncology Partners with Sensus Healthcare to Provide First Superficial Radiotherapy Services in a Mobile Configuration
Sensus Healthcare has partnered with Pompano Veterinary Oncology to introduce mobile superficial radiotherapy (SRT) for treating companion animals in South Florida. This innovative service aims to provide high-quality cancer treatment while minimizing stress for pets by offering home visits and clinic services. The SRT-100 system will enhance the clinic's existing oncology offerings.
Read more →SRTSREVISED - Sensus Healthcare Reports Third Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter
Sensus Healthcare reported a significant increase in revenues for Q3 2024, with a 127% rise compared to Q3 2023. The company achieved profitability and signed multiple agreements under its new revenue-sharing model. Management anticipates continued growth driven by the demand for SRT treatments for skin cancer. The company also highlighted the potential of its proprietary software in enhancing operational efficiency.
Read more →SRTSSensus Healthcare to Host Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 14, 2024
Sensus Healthcare, Inc. will hold a conference call on November 14, 2024, to discuss its third quarter financial results and provide a business update. The call will include discussions on recent milestones and future plans. Participants can pre-register for the call or join via dial-in options.
Read more →SRTSSensus Healthcare Sells SRT System to Providence Swedish Hospital
Sensus Healthcare has shipped an SRT system to Providence Swedish Hospital, enhancing their oncology capabilities. The system is noted for its effectiveness in treating skin cancers and is part of a growing trend towards non-invasive treatments. The CEO expressed optimism about increasing inquiries from hospitals nationwide for such technologies.
Read more →SRTSSensus Healthcare Issues Reminder That its Second Quarter 2024 Financial Results and Business Update Conference Call Will be Held on Thursday, August 8, 2024
Sensus Healthcare, Inc. will hold a conference call on August 8, 2024, to discuss its second quarter financial results and provide a business update. The call will include discussions on recent and upcoming milestones. Participants can pre-register for the call or access it via phone. A replay will be available after the call.
Read more →SRTSLargest Veterinary Emergency Hospital in Tel Aviv Acquires Sensus Healthcare’s SRT-100™ to Provide Gentler Radiotherapy to Treat Tumors in Dogs and Cats
Sensus Healthcare has announced the first commercial sale of its SRT-100 system for veterinary use outside the U.S. to Chavat Da’at in Tel Aviv. This system will provide a gentler radiotherapy option for treating tumors in dogs and cats. The sale signifies a growth opportunity for Sensus in the veterinary sector, expanding access to advanced treatment options for pet owners.
Read more →SRTSSensus Healthcare Announces Sale of First SRT-100 Vision™ System to Asia
Sensus Healthcare has announced the sale of its first SRT-100 Vision system to Far Eastern Memorial Hospital in Taiwan, a significant milestone for the company in the Asian market. The hospital plans to research new indications for the system, which could lead to expanded uses beyond non-melanoma skin cancer. This sale is expected to pave the way for further sales in the region, including China.
Read more →Competitive Position
How SRTS ranks across every disease it competes inCompetitive Position is a premium feature
See how SRTS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial